Cascadian Therapeutics, Inc.

( )
ONTY PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Medical Specialties
DHRDanaher Corp.
MDTMedtronic Plc
ABTAbbott Laboratories
TMOThermo Fisher Scientific, Inc.
BDXBecton, Dickinson & Co.
SYKStryker Corp.
BAXBaxter International, Inc.
ISRGIntuitive Surgical, Inc.
BSXBoston Scientific Corp.
EWEdwards Lifesciences Corp.
ALGNAlign Technology, Inc.
WMGIWright Medical Group NV
DXCMDexCom, Inc.
PODDInsulet Corp.

Company Profile

Cascadian Therapeutics, a clinical-stage biopharmaceutical company, researches and develops, and sells therapeutic products for the treatment of cancer in the United States. The company lead clinical-stage product candidate is tucatinib, an orally active and HER2-selective small molecule tyrosine kinase inhibitor, which is in two Phase Ib trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin. It is also developing Checkpoint kinase 1, a protein kinase that is in pre-clinical studies to regulate the cell division cycle, as well as to DNA damage and replication stress. In addition, the company focuses on the development of novel antibodies and T-cell immunoreceptor with Ig and ITM domains, an inhibitory receptor expressed on T-cells and NK cells that negatively regulate immune response to cancers. It has a license agreement with Array BioPharma Inc. to develop, manufacture and commercialize tucatinib; research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; and collaboration agreement with Adimab LLC for the discovery of novel antibodies against d immunotherapy targets in oncology.